Dr Cigall Kadoch

Cigall Kadoch, Ph.D., is an innovative academic investigator as well as entrepreneur in the biomedical sciences. She is currently an Associate Professor of Pediatric Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, Institute Member and Epigenomics Program Co-Director at the Broad Institute, and an Investigator of the Howard Hughes Medical Institute (HHMI). Dr. Kadoch established her independent laboratory in 2014, at age 27, immediately following completion of her Ph.D. studies at Stanford University. 

She is a leading expert in chromatin and gene regulation and is internationally recognized for her groundbreaking studies in these areas leading to recent clinical translation. Specifically, her laboratory studies the structure and function of nuclear protein complexes called chromatin remodeling complexes that govern DNA architecture and gene expression, perturbations in which are implicated in over 50% of human cancers, including their roles as oncogenic drivers of several aggressive pediatric cancers. Based on her seminal work, Dr. Kadoch is also the Scientific Founder of Foghorn Therapeutics (NASDAQ: FHTX), a company advancing a new class of medicines in oncology and beyond.